Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Kelun-Biotech Announces Approximately US$250 Million Placement
Details : The financing from the placement will be used to advance the clinical development of Suterai (trastuzumab botidotin), which is being evaluated for the treatment of HER2-positive breast neoplasms.
Product Name : Suterai
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
June 05, 2025
Kelun-Biotech’s SKB518 Gets FDA IND Clearance for ADC Drug Trial
Details : SKB518 is a novel ADC drug with potential first-in-class target and proprietary intellectual property rights. It is being evaluated for the treatment of advanced solid tumors.
Product Name : SKB518
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 21, 2025
Lead Product(s) : Sacituzumab Tirumotecan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kelun-Biotech's Sac-TMT Approved for Second Indication in EGFRm NSCLC
Details : SKB264 (sacituzumab tirumotecan) is a TROP-2 targeting ADC, being investiated in adult with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer.
Product Name : Jiataile
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Sacituzumab Tirumotecan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tagitanlimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kelun-Biotech's Tagitanlimab Approved for Second Indication in Recurrent NPC Treatment
Details : KL-A167 (tagitanlimab) is a PD-L1 inhibitor, is being investigated in combination with cisplatin and gemcitabine for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC).
Product Name : KL-A167
Product Type : Antibody
Upfront Cash : Inapplicable
January 23, 2025
Lead Product(s) : Tagitanlimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacituzumab Tirumotecan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kelun-Biotech's Sacituzumab Tirumotecan Approved in China for Advanced TNBC
Details : Sac-TMT (sacituzumab tirumotecan) is a TROP2-directed antibody–drug conjugate which is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC.
Product Name : SKB264
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
November 27, 2024
Lead Product(s) : Sacituzumab Tirumotecan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kelun-Biotech’s SKB264 NDA Accepted for Advanced EGFR-Mutant NSCLC
Details : SKB264 (sacituzumab tirumotecan) is a TROP-2 targeting ADC, being investiated in adult with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer.
Product Name : SKB264
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 31, 2024
Kelun-Biotech's TROP2-ADC SKB264 NDA Accepted for Advanced NSCLC
Details : SKB264 (sacituzumab tirumotecan) is being evaluated in late-stage clinical trial studies with locally advanced or metastatic epidermal growth factor receptor-mutant non-small cell lung cancer.
Product Name : SKB264
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 20, 2024
Reset All
